SAN DIEGO, May 25, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced today that the Company’s stockholders have elected Mark Wiggins as a new member of the Company’s Board of Directors. Zogenix’s stockholders also re-elected Cam L. Garner and Louis C. Bock to the Board. Mr. Wiggins will also serve as a member of the Compensation Committee of the Board.
